Real-World Outcomes With High-Dose Anti-VEGF Therapy in nAMD: Insights From the SPECTRUM Study

Real-world SPECTRUM data shows strong fluid resolution and vision gains by week 12, with low adverse events and no retinal vasculitis.

Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients.